Disease relevance of Xenetix

• CONCLUSIONS: This study confirmed that P743 remains more intravascular than iobitridol, which may have clinical implications for the diagnosis of pulmonary embolism, for example [1].
• Dynamic single-section CT of the liver was performed after intravenous bolus administration of a low-molecular-mass contrast agent (iobitridol) and an experimental high-molecular-mass agent (P840) in normal control rabbits and in rabbits with hepatic fibrosis [2].
• METHODS: In a rat acute renal failure (ARF) model, iobitridol or iohexol (both at the dose of 2.87 g I/kg) were injected to rats after pretreatment with indomethacin and N omega-nitro-L-arginin methyl ester [3].
• Evaluation of the renal tolerance of Xenetix in patients with chronic renal failure [4].
• Chronic administration (daily injections i.v. injection over 4 weeks) in the rat and dog did not demonstrate any particular toxicity for iobitridol [5].

High impact information on Xenetix

• All CT examinations were performed with retrospective electrocardiogram gating at a mean heart rate of 64 +/- 5 beats/min; 120 ml of Xenetix 300 (Guerbert GmbH, Sulzbach, Germany) were continuously injected [6].
• RATIONALE AND OBJECTIVES: To compare the pharmacokinetics of a new macromolecular iodinated contrast medium, prototype P743, with a standard contrast agent (iobitridol) for spiral computed tomography pulmonary angiography in rabbits [1].
• RESULTS: In contrast to Iohexol, which displays several interactions including one in the active site, Iobitridol is unable to interact directly with elastase [7].
• Iobitridol, a new nonionic, low-osmolality urographic and angiographic contrast medium, is a marker of extracellular fluid [8].
• PURPOSE: To study the effects of iobitridol, a nonionic contrast medium, on the electrocorticography and the blood-brain barrier structure in rabbits [9].

Chemical compound and disease context of Xenetix

• Seven patients (0.8%) receiving iobitridol 350 suffered ventricular fibrillation requiring DC cardioversion compared with none in the iopamidol 340 group (p = < 0.01) [10].

Anatomical context of Xenetix

• We have developed a method for determining iobitridol in body fluids using high-performance liquid chromatography with ultraviolet detection [11].
• Clinical tolerance and diagnostic efficacy of iobitridol 300 in lower limb angiography [12].

Associations of Xenetix with other chemical compounds

• Iodixanol significantly lowered BP in Wistar rats (-33 +/- 9% of baseline, 10 min post-injection, P < 0.001 vs. saline and iobitridol) [13].
• In response to: K. Vijayalakshmi, et al, vol. 16, no. 12, pp. 707-711: A prospective, randomized trial to determine the early and late reactions after the use of iopamidol 340 (Niopam) and iobitridol 350 (Xenetix) in cardiac catheterization [14].
• In response to: K. Vijayalakshmi, et al, vol. 16, no. 12, pp. 707-711: A prospective, randomized trial to determine the early and late reactions after the use of iopamidol 340 (Niopam) and iobitridol 350 (Xenetix) in cardiac catheterization [15].

Gene context of Xenetix

• The decrease in v(RBC) following iobitridol injection (standardized difference (SD) according to Cohen, 0.67) can be regarded as biometrically weak, and the increase following normal saline injection (SD, 0.24) as very weak [16].

Analytical, diagnostic and therapeutic context of Xenetix

• Electrocorticographic evaluation of iobitridol, a nonionic contrast medium, during selective cerebral arteriography in rabbits [9].
• Computed tomography vascular imaging was performed after intravenous injection of P743 (300 mg I/kg) in rabbits and compared with the nonspecific nonionic agent iobitridol [17].
• Iobitridol is a new non-ionic, low-osmolality contrast medium for urography and angiography [11].
• In the first part of the investigation, the kidneys were fixed by perfusion for light and electron microscopy 2 h after injection of 3 g iodine/kg of iopamidol, iobitridol or iohexol [18].
• A comparison of the efficacy and safety of ioxaglate and iobitridol in renal angioplasty [19].

References